Exploring the Efficacy of Pharmacogenomic Testing in Personalizing Antidepressant Therapy
DOI:
https://doi.org/10.29070/cxnr3486Keywords:
Pharmacogenomic Testing, Efficacy, Antidepressant TherapyAbstract
Pharmacogenomic testing has the potential to transform the way depression is treated by tailoring antidepressant medication to each person's unique genetic makeup. In order to improve antidepressant medication selection, dosing, and patient outcomes, this research investigates how well pharmacogenomic testing works. To determine the efficacy of pharmacogenomic-guided therapy in comparison to conventional treatment methods, a systematic evaluation of relevant clinical trials, meta-analyses, and real-world data was performed. According to the results, pharmacogenomic-guided treatment has many advantages over traditional techniques, including a shorter time to remission, fewer side effects, and a greater response rate. This research highlights the promise of pharmacogenomics in improving the accuracy of antidepressant treatment, decreasing the need for trial-and-error prescriptions, and, in the end, alleviating depression patients' quality of life. To really reap the benefits of this tailored strategy, further study and wider use are required.
References
Aboelbaha S., Zolezzi M., Abdallah O., Eltorki Y. (2023). Mental health prescribers' perceptions on the use of pharmacogenetic testing in the management of depression in the Middle East and North africa region. Pharmgenomics Pers. Med. 16, 503–518.
Aldrich S. L., Poweleit E. A., Prows C. A., Martin L. J., Strawn J. R., Ramsey L. B. (2019). Influence of CYP2C19 metabolizer status on escitalopram/citalopram tolerability and response in youth with anxiety and depressive disorders. Front. Pharmacol. 10, 99.
Anderson B. J., Holford N. H. (2013). Understanding dosing: Children are small adults, neonates are immature children. Arch. Dis. Child. 98 (9), 737–744.
Barker C. I. S., Groeneweg G., Maitland-van der Zee A. H., Rieder M. J., Hawcutt D. B., Hubbard T. J., et al. (2022). Pharmacogenomic testing in paediatrics: Clinical implementation strategies. Br. J. Clin. Pharmacol. 88 (10), 4297–4310.
Bousman C. A., Forbes M., Jayaram M., Eyre H., Reynolds C. F., Berk M., et al. (2017). Antidepressant prescribing in the precision medicine era: A prescriber's primer on pharmacogenetic tools. BMC Psychiatry 17 (1), 60.
Brothers K. B. (2013). Ethical issues in pediatric pharmacogenomics. J. Pediatr. Pharmacol. Ther. 18 (3), 192–198.
Chermá M. D., Ahlner J., Bengtsson F., Gustafsson P. A. (2011). Antidepressant drugs in children and adolescents: Analytical and demographic data in a naturalistic, clinical study. J. Clin. Psychopharmacol. 31 (1), 98–102.
Gassó P., Rodríguez N., Mas S., Pagerols M., Blázquez A., Plana M. T., et al. (2014). Effect of CYP2D6, CYP2C9 and ABCB1 genotypes on fluoxetine plasma concentrations and clinical improvement in children and adolescent patients. Pharmacogenomics J. 14 (5), 457–462.
Gast A., Mathes T. (2019). Medication adherence influencing factors-an (updated) overview of systematic reviews. Syst. Rev. 8 (1), 112.
Goodspeed A., Kostman N., Kriete T. E., Longtine J. W., Smith S. M., Marshall P., et al. (2019). Leveraging the utility of pharmacogenomics in psychiatry through clinical decision support: A focus group study. Ann. Gen. Psychiatry 18, 13.
Greenberg, P. E., Fournier, A. A., Sisitsky, T., Pike, C. T., & Kessler, R. C. (2015). The economic burden of adults with major depressive disorder in the United States (2005 and 2010). The Journal of clinical psychiatry, 76(2), 5356.
Helton, S. G., & Lohoff, F. W. (2015). Serotonin pathway polymorphisms and the treatment of major depressive disorder and anxiety disorders. Pharmacogenomics, 16(5), 541-553.
Jameson A., Fylan B., Bristow G. C., Sagoo G. S., Dalton C., Cardno A., et al. (2021). What are the barriers and enablers to the implementation of pharmacogenetic testing in mental health care settings?. Front. Genet. 12, 740216.
Jameson, A., Fylan, B., Bristow, G. C., Sagoo, G. S., Dalton, C., Cardno, A., ... & McLean, S. L. (2021). What are the barriers and enablers to the implementation of pharmacogenetic testing in mental health care settings?. Frontiers in genetics, 12, 740216.
Jukić M. M., Haslemo T., Molden E., Ingelman-Sundberg M. (2018). Impact of CYP2C19 genotype on escitalopram exposure and therapeutic failure: A retrospective study based on 2,087 patients. Am. J. Psychiatry 175 (5), 463–470.
Lazarowski, A., & Czornyj, L. (2011). Potential role of multidrug resistant proteins in refractory epilepsy and antiepileptic drugs interactions.
Liko I., Lai E., Griffin R. J., Aquilante C. L., Lee Y. M. (2020). Patients' perspectives on psychiatric pharmacogenetic testing. Pharmacopsychiatry 53 (6), 256–261.
Magarbeh, L., Hassel, C., Choi, M., Islam, F., Marshe, V. S., Zai, C. C., ... & Müller, D. J. (2023). ABCB1 Gene Variants and Antidepressant Treatment Outcomes: A Systematic Review and Meta‐Analysis Including Results from the CAN‐BIND‐1 Study. Clinical Pharmacology & Therapeutics, 114(1), 88-117.
McMillan S. S., Stewart V., Wheeler A. J., Kelly F., Stapleton H. (2020). Medication management in the context of mental illness: An exploratory study of young people living in Australia. BMC Public Health 20 (1), 1188.
Namerow L. B., Ramsey L. B., Malik S., Cortese S., Strawn J. R. (2022). Editorial: Beyond red light, green light: Examining the role of pharmacogenomics in evidence-based care in child and adolescent psychiatry. J. Am. Acad. Child. Adolesc. Psychiatry 61 (1), 29–31.
Ong C. S. B., Fok R. W., Tan R. C. A., Fung S. M., Sun S., Ngeow J. Y. Y. (2022). General practitioners' (GPs) experience, attitudes and needs on clinical genetic services: A systematic review. Fam. Med. Community Health 10 (4), e001515.
Patel, K. A., Bhatt, M. H., Hirani, R. V., Patel, V. A., Patel, V. N., Shah, G. B., & Chorawala, M. R. (2022). Assessment of potential drug–drug interactions among outpatients in a tertiary care hospital: Focusing on the role of P-glycoprotein and CYP3A4 (retrospective observational study). Heliyon, 8(11).
Pinzón-Espinosa J., van der Horst M., Zinkstok J., Austin J., Aalfs C., Batalla A., et al. (2022). Barriers to genetic testing in clinical psychiatry and ways to overcome them: From clinicians' attitudes to sociocultural differences between patients across the globe. Transl. Psychiatry 12 (1), 442.
Preys C. L., Blout Zawatsky C. L., Massmann A., Heukelom J. V., Green R. C., Hajek C., et al. (2023). Attitudes about pharmacogenomic testing vary by healthcare specialty. Pharmacogenomics 24, 539–549.
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., ... & Fava, M. (2006). Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR* D report. American Journal of Psychiatry, 163(11), 1905-1917.
Samardzic, J., Svob Strac, D., & van den Anker, J. N. (2017). The benefit and future of pharmacogenetics. Total Intravenous Anesthesia and Target Controlled Infusions: A Comprehensive Global Anthology, 697-711.
Sarginson, J. E., Lazzeroni, L. C., Ryan, H. S., Ershoff, B. D., Schatzberg, A. F., & Murphy Jr, G. M. (2010). ABCB1 (MDR1) polymorphisms and antidepressant response in geriatric depression. Pharmacogenetics and genomics, 20(8), 467-475.
Stancil S. L., Berrios C., Abdel-Rahman S. (2021). Adolescent perceptions of pharmacogenetic testing. Pharmacogenomics 22 (6), 335–343.
Stephenson T. (2005). How children's responses to drugs differ from adults. Br. J. Clin. Pharmacol. 59 (6), 670–673.
Strawn J. R., Mills J. A., Poweleit E. A., Ramsey L. B., Croarkin P. E. (2023). Adverse effects of antidepressant medications and their management in children and adolescents. Pharmacotherapy 43, 675–690.
Strawn J. R., Poweleit E. A., Ramsey L. B. (2019). CYP2C19-Guided escitalopram and sertraline dosing in pediatric patients: A pharmacokinetic modeling study. J. Child. Adolesc. Psychopharmacol. 29 (5), 340–347.
Van Westrhenen, R., Aitchison, K. J., Ingelman-Sundberg, M., & Jukić, M. M. (2020). Pharmacogenomics of antidepressant and antipsychotic treatment: how far have we got and where are we going?. Frontiers in Psychiatry, 11, 94.
Vimalachandran P., Liu H., Lin Y., Ji K., Wang H., Zhang Y. (2020). Improving accessibility of the Australian My Health Records while preserving privacy and security of the system. Health Inf. Sci. Syst. 8 (1), 31.
Yamasaki, Y., Moriwaki, T., Ogata, S., Ito, S., Ohtsuki, S., Minegishi, G., ... & Kazuki, Y. (2022). Influence of MDR1 gene polymorphism (2677G> T) on expression and function of P-glycoprotein at the blood-brain barrier: utilizing novel P-glycoprotein humanized mice with mutation. Pharmacogenetics and Genomics, 32(8), 288-292.
This work is licensed under a 